Atai Beckley N.V. share price logo

Atai Beckley N.V.

NASDAQ: ATAI

$7.39

+0.05

(+0.68%)

as on

Atai Beckley N.V. Stock Performance

as on September 5, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $7.31
    $7.41
    downward going graph

    1.08%

    Downside

    0.27%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.27
    $7.45
    downward going graph

    55.82%

    Downside

    0.81%

    Upside

    downward going graph

Atai Beckley N.V. share price movements today

Previous Close
$7.34
Open
$7.34
Volume
9.3M
Market Cap
$2.7B
Day's Low - High
$7.31 - $7.41
52 Week Low - High
$3.27 - $7.45

Atai Beckley N.V. Historical Returns

1 Month Return
+ 2.23 %
3 Month Return
+ 63.11 %
1 Year Return
+ 60.96 %
3 Year Return
+ 376.62 %
5 Year Return
-57.23 %

Atai Beckley N.V. Stock Fundamentals & Key Indicators

Check Atai Beckley N.V. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.7B

EPS (TTM)

-2.9002

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.97%

PE Ratio (TTM)

-2.53

Industry PE ratio

-13.53

PEG Ratio

0.01018184104193162

EBITDA

-679.2M

Revenue (TTM)

4.5M

Profit Margin

86.25%

Return On Equity TTM

-353.23%

Atai Beckley N.V. Stock Valuation

Track how Atai Beckley N.V. P/E has moved over time to understand its valuation trends.

Atai Beckley N.V. in the last 5 years

  • Overview

  • Trends

Lowest (-7.31x)

December 31, 2021

Industry (-13.53x)

December 31, 2025

Today (-1.41x)

December 31, 2025

Highest (-1.41x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.41x

Atai Beckley N.V. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Atai Beckley N.V. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Atai Beckley N.V. image
Atai Beckley N.V.
BUY$2.7B-57.23%-2.5386.25%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$141.1B181.73%32.2186.04%NA
Moderna image
Moderna
BUY$60.2B-64.27%-18.66-12.57%NA
Regeneron image
Regeneron
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Atai Beckley N.V. Stock including INR - Dollar returns

The Atai Beckley N.V. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Atai Beckley N.V. investment value today

Current value as on today

₹1,73,623

Returns

₹73,623

(+73.62%)

Returns from Atai Beckley N.V. Stock

₹62,061 (+62.06%)

Dollar Impact

₹11,562 (+11.56%)

Analyst Recommendation on Atai Beckley N.V. Stock

Based on 12 analysts

BUY

8.33%

Buy

91.67%

Hold

0.00%

Sell

Based on 12 analysts, 91.66666666666666% of analysts recommend a 'BUY' rating for Atai Beckley N.V.. Average target price of $8.1

Atai Beckley N.V. Share Price Target

Get share price movements and forecasts by analysts on Atai Beckley N.V..

What analysts predicted

8.77%UPSIDE

Target Price

$8.1

Current Price

$7.39

Analyzed by

12 Analysts

Target

$8.10

Atai Beckley N.V. target price $8.1, a slight upside of 8.77% compared to current price of $7.39. According to 12 analysts rating.

Indian Investors' Interest in Atai Beckley N.V. Stock

Search interest for Atai Beckley N.V. Stock has decreased by -65% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-65% versus previous 30 day period

Atai Beckley N.V. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
0
0
0
1
0
0
1
0
1
Gross Profit
0
0
0
-17
1
0
0
1
0
1
Operating Income
-23
-25
-22
-30
-20
-25
-28
-42
-30
-44
EBITDA
-26
-56
-25
-29
-25
-27
-60
-544
-29
-43
Interest Expense
0
0
0
0
0
0
-
-
-
-
Depreciation
0
0
0
0
0
0
0
-
0
0
Income Before Tax
-27
-57
-26
-39
-26
-27
-60
-544
-29
-32
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-26
-57
-26
-38
-26
-27
-61
-544
-29
-32
Net Profit Margin
0.00%
100.00%
100.00%
100.00%
86.11%
68.43%
68.89%
100.00%
82.49%
87.38%

Atai Beckley N.V. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
20
0
0
0
4
Gross Profit
0
0
20
0
0
0
3
Operating Income
-17
-104
-120
-144
-125
-102
-99
EBITDA
-17
-104
-178
-150
-39
-147
-657
Interest Expense
-
-
-
0
2
3
1
Depreciation
0
0
0
0
0
0
1
Income Before Tax
-24
-178
-178
-151
-42
-150
-659
Income Tax Expense
0
0
-3
6
1
0
0
Net Income
-14
-169
-167
-152
-40
-149
-660
Net Profit Margin
0.00%
0.00%
100.00%
100.00%
100.00%
-53.57%
75.25%

Atai Beckley N.V. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-27
-57
-26
-38
-26
-27
-61
-544
-29
-32
Operating Cash Flow
-22
-16
-19
-24
-17
-14
-23
-48
-21
-35
Investing Cash Flow
11
16
24
6
-11
9
-67
-40
-21
158
Financing Cash Flow
-
0
4
0
59
7
59
144
0
2
Change in Cash
-11
10
10
-17
30
3
-31
54
-42
125

Atai Beckley N.V. Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-24
-178
-174
-157
-43
-150
-660
Operating Cash Flow
-7
-20
-63
-104
-84
-82
-102
Investing Cash Flow
-9
-28
-81
-86
-53
59
-109
Financing Cash Flow
40
113
409
20
-8
5
269
Change in Cash
23
67
265
-171
-145
-17
57

Mutual Funds that own Atai Beckley N.V. Stock

Check out the Mutual Funds with significant holdings in Atai Beckley N.V..

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.089839%
11459122
MORGAN STANLEY INSTITUTIONAL FUND INC
0.21829%
809563
Fidelity Concord Street Trust
0.103765%
384831
VANGUARD VALLEY FORGE FUNDS
0.044322%
164377
VANGUARD INSTITUTIONAL INDEX FUNDS
0.036839%
136623
See all

Global Institutional Holdings in Atai Beckley N.V.

Funds
Holdings
iShares
4.3%
Vanguard
3.87%
SPDR
0.99%
Cathie Wood
0.89%
First Trust
0.61%
See all

Atai Beckley N.V. News & Key Events

  • img

    Today's Timeline - 16 July

    Thu, 05:03 PM

    -

    AtaiBeckley agrees to be acquired by Eli Lilly for $6.75 per share, plus potential milestone payments.

Insights on Atai Beckley N.V.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, ATAI stock has moved up by 87.1%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 953.99K → 1.70M (in $), with an average increase of 44.0% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ATAI has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 479.0% return, outperforming this stock by 417.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -29.78M → -32.52M (in $), with an average decrease of 9.2% per quarter

About Atai Beckley N.V.

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
OrganisationAtai Beckley N.V.
Headquarters250 West 34th Street, New York, NY, United States, 10119
IndustryBiotechnology
CEODr. Srinivas G. Rao M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Atai Beckley N.V.

Name

Title

Dr. Kevin Craig M.D.

Chief Medical Officer

Ms. Kavita Panke

Senior Vice President of New Product, Planning & Commercial

Mr. Ryan Barrett J.D.

Chief Legal & Business Officer

Dr. Glenn Short Ph.D.

Chief Scientific Officer

Dr. Gerd G. Kochendoerfer Ph.D.

Chief Operating Officer

Mr. Michael Eric Faerm

Chief Financial Officer

Dr. Jason Awe Ph.D.

Vice President of Investor Relations

Dr. Robert Conley M.D.

Chief Research & Development Officer

Mr. Christian Angermayer

Co-Founder & Chairman of the Board

Dr. Srinivas G. Rao M.D., Ph.D.

Co-Founder, CEO & Executive Director

FAQs

What is Atai Beckley N.V. share price today?

Atai Beckley N.V. share price today is $7.39 as on at the close of the market. Atai Beckley N.V. share today touched a day high of $7.41 and a low of $7.31.

What is the 52 week high and 52 week low for Atai Beckley N.V. share?

Atai Beckley N.V. share touched a 52 week high of $7.45 on and a 52 week low of $3.27 on . Atai Beckley N.V. stock price today i.e. is closed at $7.39,which is 0.81% down from its 52 week high and 126.34% up from its 52 week low.

What is Atai Beckley N.V.'s market capitalisation today?

Atai Beckley N.V. market capitalisation is $0.00T as on .

How to invest in Atai Beckley N.V. Stock (ATAI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Atai Beckley N.V. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Atai Beckley N.V. Shares that will get you 0.2030 shares as per Atai Beckley N.V. share price of $7.39 per share as on September 5, 2026 at 8:45 am IST.

What is the minimum amount required to buy Atai Beckley N.V. Stock (ATAI) from India?

Indian investors can start investing in Atai Beckley N.V. (ATAI) shares with as little as ₹94.485 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.85 in Atai Beckley N.V. stock (as per the Rupee-Dollar exchange rate as on ). Based on Atai Beckley N.V. share’s latest price of $7.39 as on September 5, 2026 at 8:45 am IST, you will get 1.3532 shares of Atai Beckley N.V.. Learn more about fractional shares .

What are the returns that Atai Beckley N.V. has given to Indian investors in the last 5 years?

Atai Beckley N.V. stock has given -57.23% share price returns and 29.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?